Interventional cardiologists and cardiac surgeons at Penn Medicine are performing transcatheter aortic valve replacement (TAVR) surgery for patients with aortic stenosis who are not candidates for open-heart surgery.
As original investigators in the PARTNER trial  that led to Food and Drug Administration approval for the first transcatheter aortic heart valve for aortic stenosis, cardiac specialists at Penn are among the most experienced in the country performing transcatheter aortic valve replacement.
In adults, aortic stenosis is now primarily a condition caused by age-related calcium deposition at the valve, and degenerative calcific aortic stenosis is the primary indication for aortic valve replacement in symptomatic patients. Other, less common etiologies include congenital disease, rheumatic fever and stenosis arising from radiotherapy and other treatments.
Open-heart valve replacement surgery is the gold standard treatment for otherwise healthy patients with aortic stenosis. Because the physical demands of the procedure and other comorbidities may be prohibitive, however, many older patients are not candidates for open surgery.
A relatively new approach, transcatheter aortic valve replacement (TAVR) employs a biological valve crimped onto a stent and folded inside a large bore catheter. The catheter is introduced at the groin and threaded up the aorta. Upon reaching the aortic valve, a balloon is inflated to deploy the stented valve directly over the calcified native valve, typically eliminating the need for surgical removal.
In the PARTNER trial, the transcatheter valve proved to be significantly superior to medical treatment in inoperable patients with severe symptomatic aortic stenosis. Penn researchers are now involved in the second phase of the trial, which is investigating a new and better valve design coupled with a smaller diameter delivery system that permits less invasive access at the groin.
Mr. L, an 88-year-old man, was referred to Penn Interventional Cardiology by his community cardiologist after a decade of progressive heart failure (LVEF 30%) when an echocardiogram demonstrated a heavily calcified aortic valve. Mr. L had no signs of concomitant organ dysfunction and was in otherwise relatively good health. Because he was frail, however, he was felt to be inoperable.
At Penn, a physical examination revealed signs (a low-intensity carotid pulse and a pronounced heart murmur), indicative of aortic stenosis. After an angiogram demonstrated the patency of his iliac and coronary arteries and lung and kidney function were determined to be good, Mr. L was judged a good candidate for transcatheter aortic valve replacement surgery. After a consultation, he agreed to have the procedure.
The surgery proceeded without complications. Following anesthesia, the right femoral artery was dilated and a sheath introduced and advanced to the thoracic aorta. A guide wire was then threaded to the heart and the artificial valve advanced to the aortic valve. Mr. L’s heart was then paced to halt ejection, and the artificial valve was inflated over the damaged native aortic valve. Mr. L remained in the hospital for five days, after which he went home to recuperate.
At his six-month follow-up evaluation, echocardiography showed near-normal left ventricular function, and Mr. L reported notably improved quality of life.
Penn Heart and Vascular Center
Perelman Center for Advanced Medicine
East Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
Penn Presbyterian Medical Center
Heart Institute Building, Suite 2A
51 N 39th Street
Philadelphia, PA 19104
Published on: April 18, 2018
1. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, for the PARTNER Trial Investigators. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. N Engl J Med. 2011;364:2187-2198.
About Penn Interventional Cardiology
Penn Interventional Cardiology is comprised of a team of nationally recognized interventional cardiologists working in close collaboration with cardiac surgeons and cardiologists to perform catheter-based procedures for a variety of cardiovascular disorders.
Penn Faculty Team
Vice Chief, Division of Cardiovascular Surgery
Director, Thoracic Aortic Surgery Program
Co-Director, Transcatheter Valve Program
Brooke Roberts - William Maul Measey Professor in Surgery
Director, Cardiac Catheterization Laboratories, Hospital of the University of Pennsylvania
Health System Director for Interventional Cardiology
John Winthrop Bryfogle Professor of Cardiovascular Diseases
Professor of Medicine in Surgery
Director, Thoracic Aortic Surgery Research Program
Associate Professor of Surgery at the Hospital of the University of Pennsylvania
Director, Peripheral Intervention
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Co-Director, Transcatheter Aortic Valve Replacement Program, Penn Presbyterian Medical Center
Chief of Cardiovascular Surgery at Penn Presbyterian Medical Center
Vice Chief of Clinical Operations and Quality, Division of Cardiovascular Surgery
Surgical Director, Transcatheter Cardio-Aortic Therapies
Professor of Surgery at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia